In this video, Motley Fool health-care analyst Max Macaluso takes a closer look at the leadership of Amarin (NAS: AMRN) , maker of the triglyceride-lowering blockbuster drug Vascepa, and tells you what you need to know about leadership when considering whether to buy. Amarin's current CEO, Joseph Zakrzewski, has an ironic twist in his past that gives him key insight into Vascepa's biggest competitor. Since many consider Amarin to be a potential buyout target, Zakrzewski's unique knowledge will give him an edge if options like that come to the table.
The biotech space can make or break investors overnight, and when you're talking about Amarin, the success of its new triglyceride-lowering drug is key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with top Fool.com analyst Max Macaluso's premium research report. Click here now to keep reading.
The article Amarin's Leadership: Who's at the Helm? originally appeared on Fool.com.
Austin Smith and Max Macaluso, Ph.D. have no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.